1-20 of 43
Aibin Liang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Wenbin Qian, Wen Lei, Hui Liu, Wei Chen, Yun Liang, Yi Eve Sun, Xiangmin Tong, Aibin Liang
Journal: Blood
Blood (2024) 144 (Supplement 1): 7209.
https://doi.org/10.1182/blood-2024-202988
Published: 2024
Journal Articles

A New Prognostic Scoring Model in Myelodysplastic Neoplasms

Baoqing Yang, Jie Zhou, Hao Wu, Shaoguang Li, Aibin Liang, Jianfei Fu
Journal: Blood
Blood (2024) 144 (Supplement 1): 6702.
https://doi.org/10.1182/blood-2024-202368
Published: 2024
Journal Articles

Optimal Timing and Impact of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult T-Cell Lymphoblastic Lymphoma: Insights from a Large Cohort Multi-Center Real-World Study in Shanghai

Fangfang Yu, Jiahua Niu, Jianmin Yang, Jian Hou, Siguo Hao, Aibin Liang, Hong Xiong, Qi Zhu, Ligen Liu, Jun Shi, Juan Du, Bobin Chen, Rong Wei, Wenli Zhao, Lihua Sun, Yunhua Hou, Rong Tao, Xianmin Song
Journal: Blood
Blood (2024) 144 (Supplement 1): 7818.
https://doi.org/10.1182/blood-2024-199964
Published: 2024
Journal Articles

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li, Jian Ge, Shiguang Ye, Lili Zhou, Yiming Gong, Huaying Ruan, Hosein Kouros-Mehr, Aibin Liang
Journal: Blood
Blood (2024) 144 (Supplement 1): 3475.
https://doi.org/10.1182/blood-2024-199236
Published: 2024
Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6524.
https://doi.org/10.1182/blood-2024-208414
Published: 2024
Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Wang Ying, Lulu Lv, Yongping Song, Xudong Wei, Hongsheng Zhou, Qifa Liu, Kailin Xu, Dongmei Yan, Cheng Zhang, Shuangyou Liu, Jie Jin, Heng Mei, Ting Niu, Aibin Liang, Runxia Gu, Chunmei Zheng, Yi Feng, Wenqiu Huang, Shuai Xin, Wei Jin, Lin Shi, Yongzeng Wang, Jianxiang Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4196.
https://doi.org/10.1182/blood-2024-199983
Published: 2024
Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3377.
https://doi.org/10.1182/blood-2024-206742
Published: 2024
Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2024-204620
Published: 2024
Journal Articles

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Fangce WANG, Bing Li, Ping Li, Shiguang Ye, Lili Zhou, Wenjun Zhang, Shaoguang Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6865.
https://doi.org/10.1182/blood-2023-185161
Published: 2023
Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Shaoguang Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6258.
https://doi.org/10.1182/blood-2023-180524
Published: 2023
Journal Articles

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Ping Li, Wei Liu, Shiguang Ye, Lili Zhou, Judy Zhu, Jiaqi Huang, Jing Li, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Xin Yao, Hui Wan, Yihong Yao, Aibin Liang, Dehui Zou
Journal: Blood
Blood (2023) 142 (Supplement 1): 2115.
https://doi.org/10.1182/blood-2023-181527
Published: 2023
Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6934.
https://doi.org/10.1182/blood-2023-188386
Published: 2023
Journal Articles

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Yuqin Song, Keshu Zhou, Lanfang Li, Aibin Liang, Yun Qin, Zhen Xia, Yongen Gu, Zisong Zhou, Alex Tian, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3024.
https://doi.org/10.1182/blood-2023-178430
Published: 2023
Journal Articles

Paired Circulating Tumor DNA in Cerebrospinal Fluid and Peripheral Blood: Reliable Technology for Diagnosing and Monitoring Primary and Secondary Central Nervous Lymphoma

Xinyu Zhu, Bing Xiu, Jingjing Zhu, Zhi-Zhang Yang, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2994.
https://doi.org/10.1182/blood-2023-189100
Published: 2023
Journal Articles

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Bin Xue, Xiu Luo, Yifan Liu, Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3515.
https://doi.org/10.1182/blood-2023-180500
Published: 2023
Journal Articles

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Bin Xue, Xiu Luo, Yifan Liu, Lili Zhou, Shiguang Ye, Shaoguang Li, Ping Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2142.
https://doi.org/10.1182/blood-2023-184885
Published: 2023
Journal Articles

ITGB3 Promotes the Progression of JAK2V617F-Positive Myeloproliferative Neoplams By Regulating Calreticulin to Inhibit Cellular Autophagy

Jie Zhou, Wenjun Zhang, Baoqing Yang, Hao Wu, Bing Li, Shaoguang Li, Aibin Liang, Jianfei Fu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2748.
https://doi.org/10.1182/blood-2023-181816
Published: 2023
Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Ping Li, Wen-Juan Yu, Lili Zhou, Min Yang, Shiguang Ye, Judy Zhu, Jiaqi Huang, Yan Zhang, Lanfang Li, Jing Zhao, Kevin Zhu, Jing Li, Chengxiao Zheng, Liping Lan, Hui Wan, Yihong Yao, Huilai Zhang, Daobin Zhou, Jie Jin, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1025.
https://doi.org/10.1182/blood-2023-182817
Published: 2023
Journal Articles

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Shiguang Ye, Lili Zhou, Yan Lu, Xiu Luo, Shaoguang Li, Ping Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6882.
https://doi.org/10.1182/blood-2023-184765
Published: 2023
Journal Articles

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Yan Lu, Shiguang Ye, Lili Zhou, Ping Li, Shaoguang Li, Aibin Liang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6925.
https://doi.org/10.1182/blood-2023-182763
Published: 2023